Johnson & Johnson Unrecognized Tax Benefits, Interest on Income Taxes Expense
Johnson & Johnson (JNJ) reported Unrecognized Tax Benefits, Interest on Income Taxes Expense of $64.00 million for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense · last filed 2026-02-11
- Johnson & Johnson unrecognized tax benefits, interest on income taxes expense for fiscal 2025 was $64.00M, a 70.51% decline from fiscal 2024.
- Johnson & Johnson unrecognized tax benefits, interest on income taxes expense for fiscal 2024 was $217.00M, a 119.19% increase from fiscal 2023.
- Johnson & Johnson unrecognized tax benefits, interest on income taxes expense for fiscal 2023 was $99.00M, a 27.21% decline from fiscal 2023.
- Johnson & Johnson unrecognized tax benefits, interest on income taxes expense for fiscal 2023 was $136.00M, a 223.81% increase from fiscal 2022.
| Period end | Unrecognized Tax Benefits, Interest on Income Taxes Expense 12 month | Unrecognized Tax Benefits, Interest on Income Taxes Expense 12 month as first filed |
|---|---|---|
| 2025-12-28 | $64.00M 10-K · filed 2026-02-11 | |
| 2024-12-29 | $217.00M 10-K · filed 2026-02-11 | |
| 2023-12-31 | $99.00M 10-K · filed 2026-02-11 | |
| 2023-01-01 | $136.00M 10-K · filed 2025-02-13 | $139.00M 10-K · filed 2023-02-16 |
| 2022-01-02 | $42.00M 10-K · filed 2024-02-16 | $44.00M 10-K · filed 2022-02-17 |
| 2021-01-03 | $32.00M 10-K · filed 2023-02-16 | |
| 2019-12-29 | $50.00M 10-K · filed 2022-02-17 | |
| 2018-12-30 | $53.00M 10-K · filed 2021-02-22 | |
| 2017-12-31 | $60.00M 10-K · filed 2020-02-18 | |
| 2017-01-01 | $7.00M 10-K · filed 2019-02-20 | |
| 2016-01-03 | $44.00M 10-K · filed 2018-02-21 | |
| 2014-12-28 | $12.00M 10-K · filed 2017-02-27 | |
| 2013-12-29 | $40.00M 10-K · filed 2016-02-24 | |
| 2012-12-30 | $41.00M 10-K · filed 2015-02-24 | |
| 2012-01-01 | $47.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |